Hyeonha Jang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hyeonha Jang has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Hwa-Jin Park
Department of Biomedical Laboratory Science, College of Healthcare Medical Science and Engineering, Inje University, 197, Inje-ro, Gimhae 50834, Republic of Korea
3 shared publications - Jae-Ho Shin
Department of Applied Biosciences, Kyungpook National University, Daegu 41566, Republic of Korea
3 shared publications - Jeong-Soo Bae
Cardiovascular Laboratory, Medical Center of Dong-A University, 26 Daesingongwon-ro, Busan 49201, Republic of Korea
3 shared publications - Min-Kyu Park
Department of Applied Biosciences, Kyungpook National University, Republic of Korea
3 shared publications - Sung-Hun Choi
Department of Biomedical Laboratory Science, College of Healthcare Medical Science and Engineering, Inje University, 197 Inje-ro, Gimhae 50834, Republic of Korea
1 shared publication
Latest Publications
- Open Access
- 12 June 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (12) , 5326
Polyphenol-Rich Oenanthe javanica as a Cardioprotective Functional Food Candidate Exhibiting Antiplatelet Activity via Suppression of Ca2+ Mobilization and Thromboxane A2 Production
Polyphenol-rich Oenanthe javanica (Blume) DC. is widely consumed in Asia but its impact on platelet activation, a cause of cardiovascular disease (CVD), is unclear. Collagen-driven platelet activation requires intracellular Ca2+ mobilization and thromboxane A2 (TXA2) production—rational targets for CVD prevention. A hot water extract of O. javanica (OJWE) was profiled by HPLC and tested on collagen-stimulated washed human platelets. Aggregation, Fura-2 [Ca2+]i, and TXB2 were measured, including combinations with verapamil, aspirin, caffeic acid (CA), and chlorogenic acid (CGA). Coagulation (PT/APTT) and ex vivo effects in Sprague–Dawley rats given OJWE (1 or 5 mg day−1, 30 days) were also evaluated. OJWE dose-dependently inhibited collagen-induced aggregation in a Ca2+-dependent manner, synergizing with verapamil, and suppressed [Ca2+]i mobilization and TXA2 production. CA and CGA synergistically enhanced aspirin-mediated COX-1 inhibition. PT/APTT were unaffected in vitro and ex vivo. Dietary OJWE modestly but significantly reduced rat platelet aggregation without altering coagulation. OJWE attenuates platelet activation by selectively targeting Ca2+ mobilization and TXA2 biosynthesis without compromising hemostasis, supporting O. javanica as a functional food with cardiovascular potential at dietary intake.
- 12 June 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (12) , 5326
Open AccessPolyphenol-Rich Oenanthe javanica as a Cardioprotective Functional Food Candidate Exhibiting Antiplatelet Activity via Suppression of Ca2+ Mobilization and Thromboxane A2 Production
Polyphenol-rich Oenanthe javanica (Blume) DC. is widely consumed in Asia but its impact on platelet activation, a cause of cardiovascular disease (CVD), is unclear. Collagen-driven platelet activation requires intracellular Ca2+ mobilization and thromboxane A2 (TXA2) production—rational targets for CVD prevention. A hot water extract of O. javanica (OJWE) was profiled by HPLC and tested on collagen-stimulated washed human platelets. Aggregation, Fura-2 [Ca2+]i, and TXB2 were measured, including combinations with verapamil, aspirin, caffeic acid (CA), and chlorogenic acid (CGA). Coagulation (PT/APTT) and ex vivo effects in Sprague–Dawley rats given OJWE (1 or 5 mg day−1, 30 days) were also evaluated. OJWE dose-dependently inhibited collagen-induced aggregation in a Ca2+-dependent manner, synergizing with verapamil, and suppressed [Ca2+]i mobilization and TXA2 production. CA and CGA synergistically enhanced aspirin-mediated COX-1 inhibition. PT/APTT were unaffected in vitro and ex vivo. Dietary OJWE modestly but significantly reduced rat platelet aggregation without altering coagulation. OJWE attenuates platelet activation by selectively targeting Ca2+ mobilization and TXA2 biosynthesis without compromising hemostasis, supporting O. javanica as a functional food with cardiovascular potential at dietary intake.
- Open Access
- 27 February 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (5) , 2254
Antithrombotic Effects of Cordycepin-Enriched WIB-801CE via Inhibition of Thromboxane A2-Induced αIIbβ3 Activation and Thrombin-Mediated Fibrin Clot Retraction
WIB-801CE, a standardized Cordyceps militaris extract containing 7.0% cordycepin, suppresses platelet activation induced by thrombin, collagen, and adenosine diphosphate (ADP). As these agonists generate thromboxane A2 (TXA2), which amplifies platelet activation via a self-propagating feedback loop, blockade of TXA2-mediated signaling offers strong antithrombotic potential. TXA2-antagonistic effects were evaluated using U46619, a stable TXA2 analog. Platelet activation was assessed by fibrinogen binding to integrin αIIbβ3, aggregation, and phosphorylation of platelet-activating proteins—PI3K (Tyr458), Akt (Ser473), p38 MAPK (Thr180/Tyr182), ERK1 (Thr202/Tyr204), JNK1 (Thr183/Tyr185)—and inhibitory proteins—VASP (Ser157) and IP3RI (Ser1756)—via immunoblotting. Thrombin-induced fibrin clot retraction, cytotoxicity, coagulation parameters, and antioxidant capacity were also examined. WIB-801CE significantly inhibited U46619-induced fibrinogen binding to integrin αIIbβ3 and platelet aggregation, without inducing cytotoxicity or impairing hemostatic function. It also significantly downregulated the phosphorylation of platelet-activating proteins and upregulated the phosphorylation of platelet-inhibiting proteins. Additionally, WIB-801CE abolished thrombin-induced fibrin clot retraction and demonstrated antioxidant capacity. WIB-801CE disrupts TXA2-driven platelet activation and thrombus stabilization by selectively modulating phosphorylation of key signaling proteins at defined regulatory sites. These properties highlight its promise as a therapeutic candidate for thrombotic disorders with platelet hyperreactivity.
- 27 February 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (5) , 2254
Open AccessAntithrombotic Effects of Cordycepin-Enriched WIB-801CE via Inhibition of Thromboxane A2-Induced αIIbβ3 Activation and Thrombin-Mediated Fibrin Clot Retraction
WIB-801CE, a standardized Cordyceps militaris extract containing 7.0% cordycepin, suppresses platelet activation induced by thrombin, collagen, and adenosine diphosphate (ADP). As these agonists generate thromboxane A2 (TXA2), which amplifies platelet activation via a self-propagating feedback loop, blockade of TXA2-mediated signaling offers strong antithrombotic potential. TXA2-antagonistic effects were evaluated using U46619, a stable TXA2 analog. Platelet activation was assessed by fibrinogen binding to integrin αIIbβ3, aggregation, and phosphorylation of platelet-activating proteins—PI3K (Tyr458), Akt (Ser473), p38 MAPK (Thr180/Tyr182), ERK1 (Thr202/Tyr204), JNK1 (Thr183/Tyr185)—and inhibitory proteins—VASP (Ser157) and IP3RI (Ser1756)—via immunoblotting. Thrombin-induced fibrin clot retraction, cytotoxicity, coagulation parameters, and antioxidant capacity were also examined. WIB-801CE significantly inhibited U46619-induced fibrinogen binding to integrin αIIbβ3 and platelet aggregation, without inducing cytotoxicity or impairing hemostatic function. It also significantly downregulated the phosphorylation of platelet-activating proteins and upregulated the phosphorylation of platelet-inhibiting proteins. Additionally, WIB-801CE abolished thrombin-induced fibrin clot retraction and demonstrated antioxidant capacity. WIB-801CE disrupts TXA2-driven platelet activation and thrombus stabilization by selectively modulating phosphorylation of key signaling proteins at defined regulatory sites. These properties highlight its promise as a therapeutic candidate for thrombotic disorders with platelet hyperreactivity.
- Open Access
- 22 October 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (11) , 2579
Theophylline Attenuates the Release of Cardiovascular Disease-Related Triglyceride and Cholesterol by Inhibiting the Activity of Microsomal Triglyceride Transfer Protein in Rat Hepatocytes
Background/Objectives: Cardiovascular diseases (CVD) remain the leading cause of diet-related mortality, with hepatic overproduction of very-low-density lipoprotein (VLDL) being a central driver of dyslipidemia. The microsomal triglyceride transfer protein (MTP) is essential for this process, and its activity is negatively regulated by cyclic adenosine monophosphate (cAMP). Theophylline, a methylxanthine found in tea, increases intracellular cAMP. This study aimed to evaluate whether physiologically relevant concentrations of theophylline could beneficially modulate lipoprotein secretion in an ex vivo model of diet-induced MTP activation. Methods: Primary hepatocytes were isolated from rats fed a high-fat, high-carbohydrate diet (HFCD). Cells were treated with 100 µM theophylline, and the secretion of triglyceride (TG), total cholesterol (TC), VLDL-cholesterol (VLDL-C), and HDL-cholesterol (HDL-C) was quantified. Hepatocellular MTP activity and atherogenic indices were also assessed. Results: Compared to untreated control cells, theophylline treatment significantly reduced the secretion of TG by 6% and TC by 24%. Specifically, VLDL-C secretion decreased by 6%, while HDL-C secretion increased substantially by 93%. These lipid-modulating effects were correlated with a 6.9% reduction in MTP activity. Consequently, significant improvements were observed in the atherogenic indices TG/HDL-C, TC/HDL-C, and the atherogenic index (AI) (p < 0.01). Conclusions: Our findings demonstrate that physiologically attainable concentrations of theophylline rebalance lipoprotein secretion by suppressing hepatic MTP activity, shifting the lipid profile toward an anti-atherogenic state. These results highlight the potential of theophylline as a functional dietary component for mitigating diet-induced dyslipidemia and reducing cardiovascular risk.
- 22 October 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (11) , 2579
Open AccessTheophylline Attenuates the Release of Cardiovascular Disease-Related Triglyceride and Cholesterol by Inhibiting the Activity of Microsomal Triglyceride Transfer Protein in Rat Hepatocytes
Background/Objectives: Cardiovascular diseases (CVD) remain the leading cause of diet-related mortality, with hepatic overproduction of very-low-density lipoprotein (VLDL) being a central driver of dyslipidemia. The microsomal triglyceride transfer protein (MTP) is essential for this process, and its activity is negatively regulated by cyclic adenosine monophosphate (cAMP). Theophylline, a methylxanthine found in tea, increases intracellular cAMP. This study aimed to evaluate whether physiologically relevant concentrations of theophylline could beneficially modulate lipoprotein secretion in an ex vivo model of diet-induced MTP activation. Methods: Primary hepatocytes were isolated from rats fed a high-fat, high-carbohydrate diet (HFCD). Cells were treated with 100 µM theophylline, and the secretion of triglyceride (TG), total cholesterol (TC), VLDL-cholesterol (VLDL-C), and HDL-cholesterol (HDL-C) was quantified. Hepatocellular MTP activity and atherogenic indices were also assessed. Results: Compared to untreated control cells, theophylline treatment significantly reduced the secretion of TG by 6% and TC by 24%. Specifically, VLDL-C secretion decreased by 6%, while HDL-C secretion increased substantially by 93%. These lipid-modulating effects were correlated with a 6.9% reduction in MTP activity. Consequently, significant improvements were observed in the atherogenic indices TG/HDL-C, TC/HDL-C, and the atherogenic index (AI) (p < 0.01). Conclusions: Our findings demonstrate that physiologically attainable concentrations of theophylline rebalance lipoprotein secretion by suppressing hepatic MTP activity, shifting the lipid profile toward an anti-atherogenic state. These results highlight the potential of theophylline as a functional dietary component for mitigating diet-induced dyslipidemia and reducing cardiovascular risk.